Key result
Exenatide once weekly demonstrated similar efficacy in reducing HbA1c (-1.46% in CKD3 vs -1.37% in CKD2) and was well tolerated in participants with type 2 diabetes and moderate versus mild renal impairment.
Why the study?
Because exenatide once weekly is primarily renally eliminated, this study evaluated its efficacy and renal and gastrointestinal tolerability in participants with type 2 diabetes and CKD stage 2 or 3.
Does exenatide once weekly improve glycemic control and maintain safety in patients with type 2 diabetes and stage 2 or 3 chronic kidney disease?
Meta-Analysis (n=2,204)
Double-blind and open-label
Randomized
Yes
Does exenatide once weekly improve glycemic control and maintain safety in patients with type 2 diabetes and stage 2 or 3 chronic kidney disease?
Absolute Event Rate: -1.46% vs -1.37%
Exenatide once weekly provides similar glycemic and weight-loss efficacy in patients with type 2 diabetes and mild or moderate CKD, though moderate CKD is associated with a higher rate of gastrointestinal adverse events.
No takes yet. Share an insight, caveat, or question.
Supports exenatide once weekly for glycemic control in type 2 diabetes with mild-moderate CKD; extends evidence to moderate renal impairment.
Guja et al. (2020) conducted a meta-analysis in Type 2 diabetes and stage 2/3 chronic kidney disease (n=2,204). Exenatide once weekly vs. Placebo or non-GLP-1 RA comparators (sitagliptin, metformin, pioglitazone, dapagliflozin, insulin) was evaluated on Change in HbA1c from baseline to week 26/28 (EQW in CKD3 vs CKD2). Exenatide once weekly demonstrated similar efficacy in reducing HbA1c (-1.46% in CKD3 vs -1.37% in CKD2) and was well tolerated in participants with type 2 diabetes and moderate versus mild renal impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: